Chapter

CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib

From ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor by Bryant Furlow

Concepts

1. Survival Outcomes

   "First-line amivantamab plus lazertinib (ami-laz) more than doubled median OS compared to historical outcomes for afatinib, at 41 months compared to 19.4 months, and 55% of patients with EGFR-mutated

2. Study Design

   "The findings come from an analysis of dose-expansion Cohort C of the open-label, multi-cohort, multinational phase 2b CHRYSALIS-2 study (NCT04077463). The researchers enrolled 49 treatment-naïve pati

3. Safety Profile

   "Treatment-emergent adverse events (TEAEs) were consistent with prior reports and included any-grade EGFR inhibition-related paronychia (78%), rash (65%), diarrhea and stomatitis (each 35%), and pruri

4. Expert Commentary

   "The team also analyzed outcomes for patients with different EGFR mutation subtypes, “both the individual amino acid changes, of which there were a few different types, and the presence of compound mu